
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc has demonstrated promising initial Phase 2 results for its EGFR MasterKey inhibitor, BDTX-1535, showing a 36% overall response rate (ORR) among evaluable patients, which improved to 42% when excluding those without on-target resistance mutations. The majority of patients in the study, 74% of 19 patients, continued treatment as of the data cutoff, suggesting a favorable tolerability profile and potential for sustained responses. Additionally, the company is positioned within an underserved market for non-classical EGFR-mutant non-small cell lung cancer (NSCLC), providing a compelling rationale for further investment, as the current available therapies do not adequately address these specific oncogenic mutations.
Bears say
Black Diamond Therapeutics Inc faces significant risks related to the efficacy and safety of its lead candidate, BDTX-1535, which could adversely affect clinical outcomes and investor confidence. The company’s financial position reflects expected continued losses, with a projected full-year 2025 net loss of $1.32 per share, indicating a challenging path to profitability. Furthermore, the adjustments to near- to mid-term expense assumptions and potential dilution risks raise concerns about the sustainability of the company's operations and its ability to achieve commercialization milestones.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares